Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammation Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for cIAP1/BIRC2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | cIAP1/BIRC2 Recombinant Protein (BIR3 Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View cIAP1 Products |
| Gene Delivery | cIAP1/BIRC2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View cIAP1 Products |
| Benchmark Ab | Anti-cIAP1/BIRC2 (Sequence of clinical benchmarks) Recombinant positive control. |
View cIAP1 Products |
| Validator | cIAP1/BIRC2 siRNA Set For knockdown verification. |
View cIAP1 Products |
| Related Target A | cIAP2/BIRC3 Homologous IAP family member; critical for off-target selectivity profiling. |
View cIAP2 Products |
| Related Target B | XIAP/BIRC4 Key apoptotic regulator; differential binding assays prevent systemic toxicity. |
View XIAP Products |
| Related Target C | DIABLO/SMAC Endogenous IAP antagonist; essential partner for competitive binding assays. |
View DIABLO Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily selectivity (cIAP1 vs. cIAP2 vs. XIAP) | Individually expressed BIR3 domain proteins, sequence verified with native-like folding. |
| E3 ligase cascade reproducibility | High-purity (>95%) full-length constructs with verified molecular weight and minimal endotoxin. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live cIAP1/BIRC2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for cIAP1/BIRC2 therapeutics is intensifying, with major players shifting focus from traditional monotherapy SMAC mimetics to PROTACs (Proteolysis Targeting Chimeras) and combination immunotherapies. As first-generation therapies reach late-stage clinical trials, the next wave of R&D is targeting the dual degradation of cIAP1 and cIAP2 to maximize TNF-alpha-mediated tumor necroptosis while avoiding systemic toxicities associated with XIAP inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| SMAC Mimetics (IAP Antagonists) | Debiopharm, Ascentage Pharma | Head and Neck Cancer, Solid Tumors | Competitive Binding Assay (Need high-purity BIR3 domain proteins) |
| PROTACs (cIAP1-recruiting) | Arvinas, Kymera Therapeutics | Hematological Malignancies, Prostate Cancer | Ternary Complex Validation (Need functional full-length E3 ligase) |
| Molecular Glues | Monte Rosa Therapeutics, Bristol Myers Squibb | Refractory Cancers, Inflammatory Diseases | Selectivity Profiling (Need mutant vs. WT protein panels) |